Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts LCTX Hot Sheet
Join SI Premium – FREE
Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.4 million .
For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
- JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
